Enveric Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.7M
- Price
- $1.50
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.70%
- Volume
- 41.4K
About
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Quick stats
Shares outstanding4.5M
Computed float3.6M
Float / shares81.0%
Cash runway (months)8.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000890821
Websitehttps://www.enveric.com
AI Summary
AI-generated1/27
minorbullishoperations update
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences received a Notice of Allowance from the USPTO for a patent application covering novel compounds in its EVM401 Series of non-hallucinogenic, mescaline-derived neuroplastogens.
This is the third U.S. patent allowance in the EVM401 Series, with expected composition-of-matter claims covering methylone-inspired benzodioxole analogs designed for potential PTSD and other psychiatric treatments.
The release contains no clinical or financial data, so the market impact is limited; for a preclinical-stage micro-cap, the IP addition is incremental rather than a catalyst, with IND submission for the pipeline remaining the more meaningful milestone to watch.
Red flags
- forward-looking boilerplate cites need for sufficient future funding and going-concern language — standard for clinical-stage micro-caps but underscores financing risk